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Abstract
Background: Achieving pregnancy by in vitro fertilization (IVF) treatment depends on many factors, including the
ovaries’ capacity and the efficiency of ovarian stimulation. The aim of this study was to assess the influence of
ovarian stimulation with human and recombinant gonadotropin, as well as specific hormonal parameters, on the
effectiveness of IVF and the dynamics of embryonic development.
Methods: The study involved 221 women aged 25–35 years in whom intracytoplasmic sperm injection was
performed. The ovarian stimulation was carried out according to the short protocol: injections of gonadotropin-
releasing hormone analogue were followed by human (hFSH) and recombinant (rFSH) follicle-stimulating hormone
administration. The growth of embryos was monitored with a time-lapse system. Levels of follicle-stimulating hormone
(FSH), luteinizing hormone (LH), and anti-Müllerian hormone (AMH) were measured before ovarian stimulation, and
levels of estradiol were assessed on the day of administration of recombinant chorionic gonadotropin.
Results: Pregnancy was achieved in 77 women (group A) – 42 (54.55 %) of them were stimulated with hFSH and 35
(45.45 %) were stimulated with rFSH. Among the 144 women in whom pregnancy was not achieved (group B), hFSH
was administered to 73 (50.69 %) women and rFSH to 71 (49.31 %) women. In both groups subsequent embryo
development stages were usually noted earlier after hFSH stimulation than after rFSH stimulation. The average values
of AMH, estradiol, and estradiol per >17 mm follicle were higher in group A; in turn, FSH and LH mean levels were
higher in group B. ROC curve analysis showed no statistically significant differences between accuracy of using FSH
and AMH levels to predict pregnancy after IVF.
Conclusions: The kind of gonadotropin applied to stimulate ovaries impacts the dynamics of embryo development -
in women stimulated with hFSH, subsequent development stages were usually observed earlier than in women
treated with rFSH; however, there was no statistically significant difference in pregnancy rates between women who
were hFSH stimulated and those who were rFSH stimulated. The mean estradiol level was higher in women who
achieved pregnancy than in women in whom pregnancy was not achieved AMH and FSH have the greater impact on
achieving pregnancy than other hormones, and the value of AMH and FSH in predicting pregnancy is similar.
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Background
Infertility is recognized as a social disease, and its preva-
lence is estimated to be around 9 % worldwide for
women in reproductive age. The method the most often
used to treat infertility is in vitro fertilization (IVF) with
intracytoplasmic sperm injection (ICSI). This method
gives the highest success rate per cycle in comparison
with other treatment options [1]. As a preparation for
IVF/ICSI, ovarian stimulation is performed in order to
induce the development of multiple follicles of the ovar-
ies. Then, oocytes are aspirated, injected with sperm,
and placed into special medium. After a few days of cul-
ture, the embryos regarded as the best-developed are
transferred into the woman’s uterus [2]. Achieving preg-
nancy by means of IVF/ICSI treatment depends on
many factors, including the capacity of the ovaries and
the performed ovarian stimulation. The ovarian reserve
is assessed i.a. on the basis of gonadotropins (follicle-
stimulating hormone – FSH and luteinizing hormone -
LH) and anti-Müllerian hormone (AMH) levels [3].
Ovarian stimulation may be performed with use human
or recombinant FSH; however, it is still not clear which
kind of gonadotropin gives better IVF outcomes [4–7].
On the other hand, although estrogens and progesterone
have been identified as the key hormones involved in the
course of oocyte maturation, which appears to be
strongly linked to a successful result in assisted
reproduction treatment, it has been not clarified whether
or not they affect the probability of pregnancy [8, 9].
IVF/ICSI outcomes may also be influenced by proper
selection of the embryo to transfer. For a long time em-
bryos were evaluated based on morphological features.
Recently, there has been a notable increase in monitor-
ing embryos in real time using a camera placed inside
the incubator. A time-lapse embryo monitoring system
enables observation of all embryos without any disturb-
ance in incubation conditions or alteration of daily rou-
tine [10–13]. The embryo growth is observed at fixed
times, and those that show better dynamics of develop-
ment are regarded as the most suitable for transfer [14].
The aim of this study was to assess the influence of
ovarian stimulation with human and recombinant go-
nadotropin, as well as specified hormonal parameters,




The presented study was conducted in the years 2013–
2014 in the “Ovum Reproduction and Andrology” Non-
Public Health Care Unit in Lublin (Poland). The study
involved 223 women undergoing IVF treatment for the
first time. The inclusion criteria were: age below 35 years,
FSH level ≤10 mIU/mL, AMH level ≥1.5 ng/mL, and
Body Mass Index (BMI) ≤30 kg/m2. Women with severe
endometriosis, metabolic disease, or leiomyoma were ex-
cluded from the study. In all women ICSI was performed
due to abnormal semen parameters. In two women em-
bryo development stopped before achieving blastocyst
stage, and therefore they were excluded from the study.
Finally, analysis was made for the 221 women in whom
embryos achieved the blastocyst stage and were trans-
ferred into uterus.
ICSI procedure
The ovarian stimulation was carried out according to a
standard ovarian stimulation protocol [2]. The short ver-
sion protocol was used because this procedure is the
most common in Poland due to reimbursement by the
Polish Government only of short-acting drugs. The
methodological part of the study is shown in Fig. 1. In
all women injections of gonadotropin-releasing hormone
analogue (GnRH) (Diphereline®: Ipsen Pharma) in a dose
0.1 IU were implemented from the first day of the men-
strual cycle. From third day of cycle women had also
daily injections of FSH in a dose 150 IU. Two types of
FSH were randomly administered: human FSH extracted
from the urine of post-menopausal women (hFSH; Fosti-
mon®: IBSA) was given to 115 women, and recombinant
FSH (rFSH; Gonal-F®: Merck-Serono) was applied to 106
women. hFSH and rFSH was administered until the 9th-
16th day of cycle when follicles with dimensions equal to
or more than 17 mm were found and serum estradiol
levels adequate to the number of follicles (over 150 pg/
mL per follicle equal to or greater than 17 mm) were
noted. Subsequently, all women were injected with
250 μg of recombinant human chorionic gonadotropin
(rhCG; Ovitrelle®: Merc-Serono). After 36 h vaginal
ultrasound-guided aspiration of oocyte-cumulus com-
plexes was performed and oocytes were placed in a
fertilization medium (COOK, Sydney IVF, Australia)
under mineral oil. Three hours after retrieval up to six
oocytes were subjected to denudation and ICSI proced-
ure. Then, the in vitro culture was carried out until day
2 (2–5 cells stage) in 25 μL of Cleavage medium
(COOK, Sydney IVF, Australia) under mineral oil in au-
tomated incubators with 5 % CO2 at 37 °C. Fifty hours
from ICSI the in vitro culture media was changed to
Blastocyst medium (COOK, Sydney IVF, Australia).
Time-lapse evaluation
The growth of all the embryos was monitored continu-
ously by obtaining images at 10-minute intervals. This
imaging was achieved with use of a compact time-lapse
microscope system (Primo Vision EVO Microscope,
Cryo-Innovation, Hungary) placed inside incubator com-
bined with a microwell embryo culture dish. During the
time-lapse observation, the embryos were not moved.
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Between image acquisitions, the system was turned off
completely to avoid exposure of the embryos to electro-
magnetic radiation.
The following terms for the timing of the stages of
embryo growth were adopted: t0 - the time when ICSI
was carried out; tF - the time of the first frame in which
both pronuclei could be observed; tC - the time of the
frame with the last observation of both pronuclei; t1 –
the time when one cell stage was observed; t2, t3, t4, t5,
t6, t7, t8, and t9 - the stages for the corresponding num-
ber of cells, e.g. t2 for 2 cells, t3 for 3 cells, etc. (stages
were annotated at the first frame in which the cells were
seen as separated by membranes); tM - the time of the
first frame in which the embryos were compacting into
the morula stage; tB - the time of the frame in which a
crescent-shaped area began to emerge from the morula;
Fig. 1 Methodological scheme of the study. (FSH – follicle-stimulating hormone, LH – luteinizing hormone, AMH – anti-Müllerian hormone, hFSH –
human follicle-stimulating hormone; rFSH – recombinant follicle-stimulating hormone; GnRHa – gonadotropin-releasing hormone analogue, rhCG –
recombinant human chorionic gonadotropin; ICSI – intracytoplasmic sperm injection; tF – time of the first frame in which both pronuclei could be
observed; tC – the frame with the last observation of both pronuclei; t1-t9 – times for corresponding numbers of cells; tM – the first frame in which
the embryos were compacting into the morula stage; tB – the frame in which a crescent-shaped area began to emerge from the morula)
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and tEB – the time of the frame with expanded blasto-
cyst with increased volume and expansion of the blasto-
coele cavity.
Based on the analysis of time-lapse records and in ac-
cordance with American Society for Reproductive Medi-
cine and the European Society of Human Reproduction
and Embryology consortium guidelines [15], a single
blastocyst was selected to be transferred into the uterus.
After 6 weeks, the presence of the embryo and its car-
diac activity were assessed via ultrasound.
Determination of hormone levels and imaging studies
Levels of FSH, LH, and AMH were determined on the
third day of the cycle preceding ovulation, before admin-
istration of drugs. Ultrasound examination was per-
formed daily since 9th day of cycle and after observation
of a follicle with dimension equal to or greater than
17 mm; daily measurement of estradiol levels was imple-
mented. The estradiol values were then converted into
the levels of estradiol per follicle equal to or greater than
17 mm (E2/f ). All hormones levels were measured in
serum obtained from morning blood samples (5 mL).
Levels of FSH, LH, and estradiol were assessed with
electrochemiluminescent method on a Cobas analyzer
(Roche Diagnostics) – the reference values were: for
FSH 3.5–12.5 mIU/mL; for LH 2.4–12.6 mIU/mL; and
for estradiol 12.5–166 pg/mL. Levels of AMH were mea-
sured with AMH Gen II ELISA test (Beckman Coulter)
on a Euroimmun analyzer (reference range > 1.5 ng/mL).
Statistical analysis
The obtained results were subjected to the Statistica 9.1
software system (StatSoft, Poland). The measurable pa-
rameters were reported as mean (M), standard deviation
(SD), and minimum (Min) or maximum (Max) whereas
the values of the immeasurable parameters were re-
ported as proportion and quantity. For quality attributes,
the Chi2 test was performed to show differences between
the examined groups. The Shapiro-Wilk normality test
was used to check the normality of distribution of vari-
ables in the examined groups. The Mann-Whitney U-
test was carried out to examine differences between the
groups. The r-Pearson correlation test was used to check
the correlations between variables. The receiver operat-
ing characteristic (ROC) curve was used to assess diag-
nostic values of the tested parameters. The significance
level was set at p <0.05, which indicates the existence of
statistically significant differences or correlations.
Ethical statement
The studies were approved by the Ethics Committee of
the Institute of Rural Health in Lublin. All women were
provided with oral and written information about the
study and signed a written consent allowing the use of
their data for research purposes.
Results
Characteristics of the studied population and the
effectiveness of IVF
The mean age of the women included in the study was
30.90 ± 2.93 years and ranged from 25 to 35 years. In
turn, the BMI of the studied women was 22.88 ±
3.27 kg/m2 and ranged from 17 to 30 kg/m2. The
women were divided into two groups according to the
results of IVF. Group A consisted of 77 women (34.8 %)
who achieved pregnancy, and group B was made up of
144 women (65.2 %) in whom pregnancy has not been
achieved. In group A, 42 women (54.55 %) were stimu-
lated with hFSH and 35 women (45.45 %) with rFSH. In
group B, hFSH was administered to 73 women (50.69 %)
and rFSH to 71 women (49.31 %) (Fig. 2). No statistically
significant difference was found between the two groups
with regards to the type of gonadotropins used (Chi2 =
0.298, df = 1, p = 0.585). Detailed information about the
studied population is presented in Table 1.
Time-lapse evaluation
Comparing time of embryo development in groups A
and B it was noted that almost all successive stages of
embryo development (except tF) occurred earlier in
women who achieved pregnancy than in women in
whom pregnancy was not achieved. However, statisti-
cally significant differences were found only between
the following time stages: tC (Z = −2.705, p = 0.007),
t1 (Z = −2.483, p = 0.013), t2 (Z = −1.985, p = 0.047), t4
(Z = −3.702, p <0.001), and tB (Z = −2.902, p = 0.004)
(Fig. 3).
Moreover, in groups A and B the timing of embryo devel-













Fig. 2 Comparison of gonadotropins administration in the group
of women who achieved pregnancy and in the group of women
in whom pregnancy was not achieved. (Group A – women who
achieved pregnancy; Group B – women in whom pregnancy was
not achieved; hFSH – human follicle-stimulating hormone; rFSH –
recombinant follicle-stimulating hormone) (Chi2 = 0.298,
df = 1, p = 0.585)
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was assessed (Fig. 4). In group A, all stages except t5 and
t8 were achieved faster in women stimulated with hFSH
than in women stimulated with rFSH, but the differ-
ences were statistically significant only for time stages
tC (Z = −2.653, p = 0.008), t2 (Z = −2.943, p = 0.003),
and t3 (Z = −2.099, p = 0.036).
In group B, faster embryo development after hFSH than
after rFSH stimulation was observed for time stages: tF,
tC, t1, t2, t3, t4, t9, and tB, and statistically significant
differences were found for all these time stages except for
t9: tF (Z = −3.572, p <0.001), tC (Z = −3.612, p <0.001), t1
(Z = −2.322, p = 0.020), t2 (Z = −3.823, p <0.001), t3 (Z = −
3.512, p <0.001), t4 (Z = −3.929, p <0.001), and tB (Z = −
4.133, p <0.001). Additionally, a statistically significant dif-
ference was noted for t6 stage that was recorded earlier
for rFSH-stimulated embryos than for embryos stimulated
with hFSH (Z = 2.026, p = 0.043).
Evaluation of hormone levels
The average values of FSH and LH were higher in group
B; in turn, levels of AMH, estradiol, and E2/f were
higher in group A (Fig. 5). The level of E2/f was statisti-
cally significant different between groups A and B (Z =
6.782, p <0.001). Similarly, estradiol (Z = 4.905, p <0.001),
FSH (Z = −4.686, p <0.001), and AMH (Z = 5.024, p <0.001)
levels differed significantly between the two groups. How-
ever, differences in LH levels (Z = −0.623, p = 0.533) were
not statistically significant (Table 2).
Correlations between hormone levels and time stages of
embryo development
The linear relationship between the various hormone
levels and the periods of embryo development was
assessed based on Pearson’s correlation coefficient (r)
(Table 3). In group A, average-level negative correlations
Table 1 Baseline characteristics of the entire studied population and groups
Group A Group B Whole population
n = 77 n = 144 n = 221
Age [years] M ± SD 30.70 ± 3.06 31.0 ± 2.68 30.90 ± 2.93
Min – Max 25 - 35 25 - 35 25 - 35
BMI [kg/m2] M ± SD 22.58 ± 3.12 23.04 ± 3.34 22.88 ± 3.27
Min – Max 17 - 30 17 - 30 17 - 30
Number of women stimulated with hFSH 42 73 115
Number of women stimulated with rFSH 35 71 106
(Group A – women who achieved pregnancy, Group B women in whom pregnancy was not achieved, BMI body mass index, hFSH human follicle-stimulating








tF tC t1 t2 t3 t4 t5 t6 t7 t8 t9 tM tB
Group A Group B
Fig. 3 Timing of subsequent embryo development stages in the group of women who achieved pregnancy and in the group of women in
whom pregnancy was not achieved. (data are expressed as mean time in hours; time stages statistically significantly different were marked with
dotted lines; Group A – women who achieved pregnancy; Group B – women in whom pregnancy was not achieved; tF – time of the first frame
in which both pronuclei could be observed; tC – the frame with the last observation of both pronuclei; t1-t9 – times for corresponding numbers
of cells; tM – the first frame in which the embryos were compacting into the morula stage; tB – the frame in which a crescent-shaped area began
to emerge from the morula)
Wdowiak and Bojar Reproductive Health  (2015) 12:113 Page 5 of 11
were found between AMH levels and t2 (r = −0.331, p =
0.003) and tB (r = −0.351, p = 0.002), and a low-level
negative correlation between AMH levels and stage t4
(r = −0.232, p = 0.042) was shown. A weak positive cor-
relation was observed between FSH levels and tB stage
(r = 0.251, p = 0.028). Weak correlations were found be-
tween LH levels and development stages as follows:
negative in t8 (r = −0.247, p = 0.030) and positive in t9
(r = 0.270, p = 0.018). For E2/f, no statistically signifi-
cant correlations with embryo development stages
were found. However, negative correlations for estra-
diol levels were observed in the following stages: t2
(r = −0.294′, p = 0.010) (low level), t4 (r = −0.363, p =
0.001) (average level), t5 (r = −0.292, p = 0.010) (slight
level), and tB (r = −0.284, p = 0.012) (slight level).
In group B, weak negative correlations were
found between AMH levels and the following
stages: t1 (r = −0.197, p = 0.018), t3 (r = −0.221, p = 0.008),
t4 (r = −0.237, p = 0.004), t6 (r = −0.185, p = 0.026), and tB
(r = −0.279, p = 0.001). Weak positive correlations were
found for FSH level at tB stage (r = 0.281, p = 0.001) and for
E2/f for t8 stage (r = 0.254, p = 0.002). For LH level, a weak
negative correlation was noted only at tF stage (r = −0.190,










tF tC t1 t2 t3 t4 t5 t6 t7 t8 t9 tM tB








tF tC t1 t2 t3 t4 t5 t6 t7 t8 t9 tM tB
Group B; hFSH Group B; rFSH
Fig. 4 Timing of subsequent embryo development stages depending on the type of gonadotropin used for ovarian stimulation in the group of
women who achieved pregnancy (a) and in the group of women in whom pregnancy was not achieved (b). (data are expressed as mean time in
hours; time stages statistically significantly different were marked with dotted lines; Group A – women who achieved pregnancy; Group B – women in
whom pregnancy has not been achieved; tF – time of the first frame in which both pronuclei could be observed; tC – the frame with the last
observation of both pronuclei; t1-t9 – times for corresponding numbers of cells; tM – the first frame in which the embryos were compacting into the
morula stage; tB – the frame in which a crescent-shaped area began to emerge from the morula)
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Fig. 5 Average hormone levels in the group of women who achieved pregnancy and in thegroup of women in whom pregnancy was not
achieved. (Group A – women who achieved pregnancy; Group B – women in whom pregnancy was not achieved; FSH – follicle-stimulating
hormone; LH – luteinizing hormone; AMH – anti-Müllerian hormone)
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were observed in the following time stages: tF (r = −0.214,
p = 0.010), t3 (r = −0.166, p = 0.047), t4 (r = −0.225, p =
0.007), and tB (r = −0.234, p = 0.005).
Prognostic value of AMH and FSH levels on the outcomes
of IVF
The accuracy of using FSH and AMH levels to predict
pregnancy after IVF was determined by ROC curve ana-
lysis (Fig. 6). An FSH level of 4.7 provides maximum dis-
crimination between whether or not pregnancy will be
achieved, with 28.57 % sensitivity and 93.75 % specificity.
Similarly, an AMH level of 3.5 has 46.75 % sensitivity
and 86.11 % specificity for indicating whether pregnancy
will be achieved. The value of area under the curve
(AUC) for FSH was 0.692, while the AUC value for
AMH was 0.705. The assumed level for α was 0.05 and
the obtained value for p was 0.597. There were no statis-
tically significant differences between the curves for FSH
or AMH (Z = 383, p = 0.702).
Table 2 Comparison of mean hormone levels in the group of
women who achieved pregnancy and in the group of women
in whom pregnancy was not achieved
Group A (n = 77) Group B (n = 144) Z p
M SD M SD
E2/f [pg/mL] 262.61 55.50 207.88 40.38 6.782 <0.001
FSH [mIU/mL] 6.35 1.96 7.73 1.84 −4.686 <0.001
AMH [ng/mL] 3.26 1.83 2.06 1.62 5.024 <0.001
Estradiol [pg/mL] 2648.66 1310.89 1770.88 1335.51 4.905 <0.001
LH [mIU/mL] 6.75 2.03 6.98 2.18 −0.623 0.533
(Z - Mann Whitney’s test result, p <0.05; Group A women who achieved
pregnancy, Group B women in whom pregnancy was not achieved, E2/f
estradiol per ≥17 mm follicle, FSH follicle-stimulating hormone, LH luteinizing
hormone, AMH anti-Müllerian hormone, M mean, SD standard deviation)
Table 3 Correlations between hormone levels and time stages of embryo development in women who achieved pregnancy and in
women in whom pregnancy was not achieved
tF tC t1 t2 t3 t4 t5 t6 t7 t8 t9 tM tB
Group A (n = 77)
E2/f [pg/mL] r −0.157 0.026 −0.098 −0.038 0.096 −0.220 −0.146 −0.048 0.074 −0.043 −0.098 0.220 −0.035
p 0.172 0.823 0.395 0.744 0.406 0.055 0.206 0.676 0.522 0.710 0.397 0.055 0.760
FSH [mIU/mL] r −0.087 −0.150 0.024 0.088 −0.076 0.080 0.041 0.088 −0.066 0.005 0.117 0.043 0.251
p 0.454 0.194 0.837 0.446 0.512 0.492 0.726 0.446 0.570 0.965 0.310 0.710 0.028
AMH [ng/mL] r −0.118 −0.154 −0.085 −0.331 −0.111 −0.232 −0.119 −0.173 −0.093 0.142 −0.013 −0.019 −0.351
p 0.306 0.180 0.460 0.003 0.336 0.042 0.301 0.133 0.422 0.219 0.912 0.871 0.002
Estradiol [pg/mL] r −0.085 −0.131 −0.193 −0.294 −0.169 −0.363 −0.292 −0.130 0.116 0.093 −0.043 0.056 −0.284
p 0.464 0.258 0.093 0.010 0.141 0.001 0.010 0.259 0.316 0.419 0.709 0.626 0.012
LH [mIU/mL] r −0.024 −0.215 −0.102 0.084 −0.059 −0.076 −0.097 0.001 0.011 −0.247 0.270 0.103 0.117
p 0.839 0.061 0.377 0.470 0.609 0.514 0.400 0.994 0.922 0.030 0.018 0.371 0.312
Group B (n = 144)
E2/f [pg/mL] r −0.034 −0.074 −0.121 0.017 −0.082 −0.151 −0.091 0.050 0.111 0.254 0.123 0.024 −0.086
p 0.685 0.376 0.149 0.844 0.330 0.071 0.281 0.551 0.185 0.002 0.143 0.774 0.305
FSH [mIU/mL] r 0.078 −0.043 0.041 0.117 0.125 0.150 −0.143 0.150 0.017 −0.155 −0.046 0.131 0.281
p 0.352 0.611 0.627 0.164 0.134 0.073 0.087 0.074 0.837 0.064 0.584 0.118 0.001
AMH [ng/mL] r −0.107 −0.132 −0.197 −0.149 −0.221 −0.237 −0.051 −0.185 0.036 0.085 −0.080 −0.048 −0.279
p 0.200 0.114 0.018 0.074 0.008 0.004 0.542 0.026 0.673 0.313 0.342 0.566 0.001
Estradiol [pg/mL] r −0.214 −0.100 −0.131 −0.072 −0.166 −0.225 −0.075 −0.142 0.074 0.068 −0.005 −0.015 −0.234
p 0.010 0.232 0.118 0.393 0.047 0.007 0.370 0.091 0.379 0.417 0.953 0.863 0.005
LH [mIU/mL] r −0.190 −0.070 0.043 −0.047 0.077 0.062 0.040 0.001 −0.009 0.045 0.133 −0.085 0.068
p 0.023 0.405 0.613 0.578 0.362 0.457 0.637 0.990 0.916 0.596 0.113 0.313 0.417
(r – Pearson’s correlation coefficient; p <0.05; Group A women who achieved pregnancy; Group B women in whom pregnancy was not achieved; E2/f estradiol per
≥17 mm follicle, FSH follicle-stimulating hormone, LH luteinizing hormone, AMH anti-Müllerian hormone, tF time of the first frame in which both pronuclei could
be observed, tC the frame with the last observation of both pronuclei, t1-t9 times for corresponding numbers of cells, tM the first frame in which the embryos
were compacting into the morula stage, tB the frame in which a crescent-shaped area began to emerge from the morula)
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Discussion
The dynamics of embryo development and IVF out-
comes are conditioned by many factors. We evaluated
the influence of gonadotropins on the timing of embryo
development with use the time-lapse monitoring, and
we compared hormones levels in women who achieved
pregnancy and in women who did not achieve pregnancy
with ICSI procedure. We are aware that other factors
such as age, BMI, or quality of oocytes can affect embryo
development and ICSI outcomes; however, in order to
make the text more clear and understandable we de-
cided to focus only on a few items.
Pregnancy, in our study, was achieved in almost 35 %
of women (group A). This ratio is comparable with re-
sults obtained by other authors e.g. Kirkegaard et al.
(31 %) and Polanski et al. (35 %) [16, 17]. Taking into
consideration the kind of gonadotropin used, we noted
that the pregnancy rate was slightly higher in women
stimulated with hFSH than in women stimulated with
rFSH; however, this difference was not statistically
significant. The observations made by Flicori et al. were
similar – they also noted higher frequency of pregnan-
cies in women treated with hFSH than in women treated
with rFSH, and their results also turn out to be statisti-
cally insignificant [6]. In turn, Kilani et al. obtained 35 %
frequency of pregnancies both for hFSH-stimulated
women and rFSH-stimulated women. However, they ob-
served that hFSH treatment was associated with a more
efficient response than stimulation with rFSH [7].
In our study, in women who achieved pregnancy al-
most all subsequent embryo development stages were
observed earlier than in women who did not achieve
pregnancy, but only part of these differences were statis-
tically significant (tC, t1,t2, t4, and tB stages). When
evaluating the impact of gonadotropins on embryos
growth we noted faster development after stimulation
with hFSH than after rFSH administration, but the dif-
ferences were significant only at stages tC, t2, and t3 in
women who achieved pregnancy and at stages tF-t4 and
tB in women who did not achieve pregnancy. Slightly
different results were obtained by Muñoz et al. – they
noted that after administration of rFSH embryos showed
better timing of development than after stimulation with
hFSH or both rFSh and hFSH; however, these differences
turned out to be not significant. Contrary to our study,
they observed no significant differences at t2 stage
between women stimulated with rFSH or hFSH or both
rFSH and hFSH. Muñoz et al. used a different protocol
for oocyte stimulation, but it seems that these diver-
gences are rather due to using different types of gonado-
tropins - in the case of hFSH they used gonadotropins
containing LH activity, and we used a medicament free
of LH [18].
Analyzing hormone levels in the studied groups, we
noted that FSH mean concentration was higher in the
group of women in whom pregnancy was not achieved,
contrary to levels of AMH, estradiol, and E2/f that were
higher in women who achieved pregnancy. Other studies
Fig. 6 Receiver operating characteristic (ROC) curve showing the sensitivity and the 1-specificity of AMH and FSH for predicting the occurrence
of pregnancy. (FSH – follicle-stimulating hormone; AMH – anti-Müllerian hormone)
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also proved that a high estradiol level improves embryos
development and IVF outcome, expressed as number of
retrieved oocytes, number of high-grade embryos, num-
ber of transferred embryos, and implementation rate
[18–22]. Munoz et al. also assessed that better IVF out-
comes are achieved when the concentration of estradiol
exceeds 2000 pg/mL. In turn, Kara et al. indicated a
4000 pg/mL value [18, 22]. Our results seems to confirm
the observation of Munoz et al. because the mean estra-
diol level in women who achieved pregnancy was about
2600 pg/mL, in contrast to women in whom pregnancy
was not achieved with mean estradiol level about
1700 pg/mL. In the present study the higher estradiol
level obtained in women who achieved pregnancy may
be due to the hFSH stimulation that was applied to over
50 % of these women. As shown by Kilani et al., treat-
ment with hFSH is associated with higher estradiol con-
centration than stimulation with rFSH [7]. Moreover, we
observed negative correlations between estradiol level
and timing of embryo development at stages t2, t4, and
t5, which is in agreement with the results obtained by
Muñoz et al. - they noted differences in the embryo dy-
namics at stage t5 and in cc2, dependent on estradiol
level, which is the duration of the period as a 2-
blastomere embryo (t3-t2) [18].
Endocrine markers thought to be useful in distinguish-
ing good and poor responders for ovarian stimulation
are, among others, FSH and AMH, but none of them is
adequate for predicting pregnancy outcomes [23]. In our
study AMH levels were significantly higher in women
who achieved pregnancy than in women in whom preg-
nancy was not achieved, and the sensitivity and specifi-
city of AMH in predicting pregnancy were 46.75 and
86.11 %, respectively. It was shown by other authors that
a low level of AMH may cause cycle cancelation, lower
mean implantation rate, or lower chances of ongoing
pregnancy [24, 25]. On the other hand, even with un-
detectable AMH, pregnancy after transfer is possible.
Therefore, as the author suggested, extremely low levels
of AMH should not be the only cause of exclusion of a
patient from attempting IVF. Then, usefulness of AMH
for forecasting pregnancy indicated in the current study
is slightly different from the observation of Reichman
et al. [25]. We also tried to check which parameter –
AMH or FSH – could be better in the prognosis of
whether pregnancy will be achieved, but due to an as-
sumed level for α at 0.05 and the obtained p value
(0.597) we cannot prove a better predictive value of any
one parameter. Hussain et al. also assessed the relation-
ships between AMH and FSH in women undergoing
IVF/ICSI, and they observed no difference in cycle
cancellation, clinical pregnancy, and live birth/ongoing
pregnancy between groups of women with different hor-
mone levels [26].
Regarding LH level, we did not show significant differ-
ences in LH concentrations between the groups of
women in whom pregnancy was or was not achieved.
Our observation is supported by results of Ramachan-
dran et al. They also showed no influence of LH level on
IVF outcomes [27].
Recently it has been suggested that the genotype of re-
ceptor for FSH should be take into account for the
pharmacological approach to infertility treatment with
FSH because the response to FSH stimulation seems to
be associated with genetic background [28]. However,
more clinical data are necessary to warrant routine use
of the FSHR isoforms as a diagnostic test.
Conclusions
1. The kind of gonadotropin applied to stimulate
ovaries impacts the dynamics of embryo
development: in women stimulated with hFSH
subsequent development stages were usually
observed earlier than in women treated with rFSH.
2. There was no statistically significant difference in
pregnancy rate between hFSH-stimulated women
and rFSH-stimulated women.
3. The mean estradiol level was higher in women who
achieved pregnancy than in women in whom
pregnancy was not achieved, and its values
negatively correlates with some time stages of
embryo development.
4. AMH and FSH had greater impact on achieving
pregnancy than other hormones, and the values of
AMH and FSH in predicting pregnancy are similar.
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